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A B S T R A C T
Introduction: The cognitive and behavioral effect of deep brain stimulation (DBS) administered to the
deep cerebral nuclei for epilepsy treatment is unknown. We investigated the cognitive outcomes at least
12 months after DBS to the bilateral anterior thalamic nucleus (ATN) for controlling intractable epilepsy.
Methods: Nine patients with intractable epilepsy who were not candidates for resective surgery, but who
were treated by bilateral ATN DBS underwent cognitive and behavioral assessments before implantation
and more than 1 year after DBS surgery. Postoperative cognitive assessments were carried out under a
continuous stimulation mode.
Results: The mean seizure-reduction rate of these patients after ATN DBS was 57.9% (35.6–90.4%).
Cognitive testing showed favorable results for verbal ﬂuency tasks (letter and category, p < 0.05), and a
signiﬁcant improvement in delayed verbal memory was observed (p = 0.017). However, we did not
observe any signiﬁcant changes in general abilities (IQ, MMSE), information processing (digit forward
and backward, Trail A, and Digit Symbol), or executive function (Trail B and WCST). Interestingly, we did
not observe any signiﬁcant cognitive decline approximately 1 year (mean, 15.9 months) after ATN DBS
surgery.
Conclusions: We showed that ATN DBS not only resulted in promising clinical effects but was also
associated with improvements in both verbal recall and oral information processing, which may be
related to the bilateral activation of the fronto-limbic circuit following DBS surgery. Further controlled,
long-term studies with larger populations are warranted for elucidating the clinical effects of ATN DBS.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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In spite of introduction of modern anti-epileptic drug (AED)
therapy, state-of-the-art of epilepsy surgery, and vagus nerve
stimulation (VNS), approximately 30% of patients continue to have
refractory seizures.1,2 Deep brain stimulation (DBS) via an
implanted neuro-stimulator system has been recognized as a
promising, alternative therapeutic choice for epilepsy.
Among various neural targets for DBS, the anterior nucleus of
thalamus (ATN) has been considered a good locus for seizure
control.3,4 Very recently, the results of a randomized, double blind,
multicenter trial (SANTE, Stimulation of the Anterior Nucleus of
Thalamus for Epilepsy) were released showing favorable thera-
peutic efﬁcacy on refractory partial or secondary generalized
epilepsy.5* Corresponding author at: Department of Neurology, The Catholic University of
Korea, St. Mary’s Hospital, 62 Yeuido-dong, Yeongdeungpo-gu, Seoul 150-713,
South Korea. Tel.: +82 2 3779 2077x1323; fax: +82 2 783 9532.
E-mail address: sonogung@catholic.ac.kr (Y.-M. Shon).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.12.003Various adverse neuropsychological changes may occur after
DBS surgery used to control movement disorders such as
Parkinson’s disease, essential tremor, or dystonia.6 Therefore, a
careful and meticulous neuropsychological (NP) testing has been a
routine and indispensable procedure ahead of the surgical
implantation to pre-empt serious post-surgical adverse effects.
However, to the best of our knowledge, no previous report has
examined the cognitive changes in detail after ATN DBS in patients
with refractory epilepsy.
The aim of this study was to investigate the long-term cognitive
effects of bilateral ATN stimulation in patients with refractory
epilepsy using a comprehensive NP testing.
2. Methods
2.1. Patients
Patients were enrolled for bilateral ATN DBS based on the
following criteria: frequent (more than 4 per a month) and
disabling seizures not controlled by multiple antiepileptic drugs
(AEDs) treatment; not candidates for resective surgical treatmentvier Ltd. All rights reserved.
Table 1
Demography of our patients with ATN DBS implantation.
Patient Diagnosis Sex Age F/U (M)
1 B F-TLE, cryptogenic F 28 60
2 Multifocal epilepsy, double cortex (B P-O) F 14 52
3 Multifocal epilepsy (P-O dominant),
cryptogenic
F 23 48
4 B FLE, symptomatic previous
meningioma resection (frontal)
M 50 28
5 B C-PLE, cryptogenic M 36 27
6 B TLE, symptomatic (B HS) M 34 25
7 B C-PLE, cryptogenic M 43 25
8 B P-OLE, symptomatic
(B perisylvian PMG)
M 31 24
9 Multifocal epilepsy, B schizencephaly F 42 22
HS: hippocampal sclerosis; FLE: frontal lobe epilepsy; F-TLE: fronto-temporal lobe
epilepsy; C-PLE: centro-parietal lobe epilepsy; P-OLE: parieto-occipital lobe
epilepsy; PMG: polymicrogyria.
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zone); patients (or caregivers) agreed to keep a daily seizure diary
for a 3-month baseline period before DBS implantation and
continuously after initiation of treatment; patients (or caregivers)
agreed that no changes to the baseline presurgical medication
regimen would be made during at least the ﬁrst year after DBS
implantation. The study was approved by the institutional review
board of Catholic University of Korea, and informed written
consent was obtained from all patients or their family members.
From our initial series of ﬁfteen patients who completed at least
1 year follow-up after implantation, 9 patients were included in
this study (Table 1). Six patients were excluded from these
reasons: three with a considerable cognitive derangement from
mental retardation (IQ < 70), not adequate for our comprehensive
NP testing; the other 3 patients underwent only one session of NP
assessment, two refused a participation in the follow-up exami-
nation, the other was not tested during the pre-operative period.
2.2. Procedures
The presurgical evaluations performed were video EEG
monitoring, optimum 1.5-T MRI, SPECT, 18-FDG PET, and full
neuropsychological assessment.Table 2
Antiepileptic drugs (AEDs) during baseline and at the time of follow-up neuro-cognitiv
Patient AEDs (/day) Baseline levels in mg/mL
(therapeutic range)
A
o
(
1 CBZ 900 mg, LTG 400 mga CBZ 9.8 (8.0–12.0) C
2 VPA 250 mg, LTG 400 mga, TPM 200 mga VPA 37.1 (50–100) V
L
3 CBZ 800 mg, TPM 300 mga, LTG 200 mga CBZ 9.6 (8.0–12.0) C
L
4 VPA 1000 mg, TPM 100 mga, OXC 1200 mga N/A V
O
5 VPA 1000 mg, LTG 400 mga VPA 68.4 (50–100) V
L
6 VPA 1200 mg, TPM 200 mga, LTG 100 mga,
PGB 150 mga
N/A V
L
7 VPA 1000 mg, LTG 100 mga VPA 49.8 (50–100) V
8 CLB 15 mga, CBZ 800 mg, VPA 500 mg,
LTG 200 mga
CBZ 8.9 (8.0–12.0);
VPA 36.3 (50–100)
C
V
9 LEV 1000 mga, LTG 200 mga, CLB 10 mga L
C
N/A: not available; CBZ: carbamazepine; VPA: valproate; TPX: topiramate; DPH: pheny
a AED serum levels not measurable at the time or not followed.
b The patient’s seizures were very frequent and much clustered (More than 95% of her
seizures or generalized seizures observed during the NPT by examiner.Our NP testing was composed of the Mini-Mental State
Examination (MMSE), the Korean Wechsler Adult Intelligence
Scale (K-WAIS), Rey–Kim Memory Test (RKMT),7 the Korean
Memory Assessment Scale (K-MAS),8,9 the Grooved Pegboard
Test,10 the Wisconsin Card Sorting Test (WSCT),11 and the frontal-
lobe function test; Trail Making Test (TMT-A and B), the Digit-Span
Test, the Word Fluency Test (category and letter), the Digit-Symbol
Substitution Test, and the Frontal Assessment Battery (FAB).12
The Rey–Kim Auditory Memory Test7 is a standardized Korean
version of the Rey Auditory Verbal Learning Test, which is known
to be a reliable measure in the detection and identiﬁcation of faulty
memory mechanisms. The administration includes ﬁve successive
presentations of a list of 15 words followed by free recall, a 20-min
delayed recall, and a 20-min delayed recognition trial. Delayed
recognition was measured with a list of 50 words in which the
subject was instructed to circle words from the learning list. The
FAB test12 included tests of similarities, lexical ﬂuency, motor
series, conﬂicting instructions, go-no-go, and prehension behavior.
Higher the scores on these tests represented better NP perfor-
mance, except for the Trail Making Test and the Grooved Pegboard
Test, for which lower scores indicated better results.
The insertion of DBS electrodes (model 3387; Medtronic1,
Minneapolis, MN) and implantable pulse generators (IPG, model
Soletra; Medtronic1) was previously described.3,4 Electrode
positioning was veriﬁed by postoperative CT (seven patients) or
MRI (two patients). Activation and programming of IPG started 1
week (seven patients) after implantation.
Our stimulation protocols of ATN DBS are differentiated from
the previous reports2,3: intermittent adjustment in stimulation
parameters (frequency 100–185 Hz, voltage 1.5–3.1 V, pulse
duration 90–150 ms, continuous stimulating mode, and in one
or two stimulated DBS electrode contacts (monopolar conﬁgura-
tions)) were carried out in all patients.1
All patients underwent the same NP testing with the implant-
able pulse generator (IPG) in the ON state at least 12 months after
ATN DBS surgery. Stimulation parameter settings remained
unchanged for at least 2 weeks before evaluation. Between the
two time points, all patients were under the same or slightly
adjusted antiepileptic drug (AED) dosage, and minimal change
(less than 1 AED) was made in their pre-operative AED
composition (Table 2).e assessment.
EDs used at the time
f the follow-up NPT
/day)
Mean post-implantation
AED levels (SD) in mg/mL
Duration of seizure
free state just
before the
follow-up NPT (day)
BZ 600 mg, LTG 400 mga CBZ 9.1 (3.2) 14
PA 250 mg, LTG 300 mga,
EV 1500 mga, TPM 100 mga
VPA 39.3 (8.8) <1b
BZ 400 mg, TPM 300 mga,
TG 200 mga, PGB 300 mga
CBZ 8.2 (2.4) 5
PA 1000 mg, TPM 100 mga,
XC 1200 mga
VPA 77.5 (6.6) 9
PA 1000 mg, LTG 300 mga,
EV 1000 mga
VPA 70.0 (9.3) 2
PA 1200 mg, TPM 200 mg,
TG 100 mg, PGB 300 mg
VPA 91.8 (10.2) 6
PA 1000 mg, LTG 100 mg VPA 53.1 (4.6) 21
LB 10 mga, CBZ 800 mg,
PA 500 mg, LTG 200 mga
CBZ 8.6 (2.4);
VPA 45.9 (7.8)
5
EV 1000 mg, LTG 200 mg,
LB 10 mg
4
toin; VGB: vigabatrin; LMT: lamotrigine; CLB: clobazam.
 seizures have been generated during breakfast). But there were no complex partial
Table 3
Seizure frequencies of the patients during long-term follow-up.
Patient Baseline 1 year 2 years 3 years 4 years 5 years Mean seizure
reductiona
1 6.3 (1.2) 3.8 (0.8)* 3.3 (1.5)* 2.3 (1.0)y 3.1 (1.3)y 3.1 (0.4)y 50.8%
2 630.5 (71.9) 576.6 (104.5) 521.8 (121.1) 468.3 (98.4) 406.0 (89.6) 35.6%
3 5.9 (0.8) 4.5 (1.2) 4.7 (0.9) 3.6 (0.5)* 2.8 (0.8)y 52.5%
4 12.0 (1.1) 4.2 (1.9)y 5.5 (2.2)* 54.2%
5 14.2 (2.3) 11.0 (2.4) 8.4 (4.7) 40.8%
6 10.4 (1.3) 2.0 (0.6)y 1.0 (0.8)y 90.4%
7 4.3 (0.7) 1.7 (0.6)y 1.1 (0.5)y 74.4%
8 15.8 (3.7) 8.0 (3.4)* 6.3 (3.9)* 60.1%
9 16.1 (4.8) 7.1 (3.1)* 6.0 (2.8)y 62.7%
Values given as absolute numbers of seizures per month (SD). Baseline seizure frequency: the number of seizures per month during 3 months before implantation.
a The ratio of the number of seizures during the last 3 months/that of baseline.
* p  0.05 (Wilcoxon rank sum test comparing yearly seizure rate with baseline).
y p  0.01 (Wilcoxon rank sum test comparing yearly seizure rate with baseline).
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Continuous variables with a normal distribution were analyzed
using paired t-tests to investigate differences between baseline
and post-operation NP results. When continuous variables showed
an asymmetric distribution, the Wilcoxon rank sum test was
performed.
We also used linear regression models to further evaluate the
relationship of long-term clinical outcome and neuro-cognitiveTable 4
Mean change in scores on neuropsychological variables between baseline and post
DBS.
Neuropsychological variable Baseline
(mean  SD)
Post DBS –
baselinea
(mean)
p valuey
IQ
Verbal IQ 85.7  11.0 1.8 0.40
Performance IQ 90.8  12.4 0.3 0.85
Total IQ 88.6  9.7 1.4 0.42
Rey–Kim Memory Test (RKMT)
Delayed verbal recall 6.8  3.1 2.2 0.017
Verbal recognition 9.3  2.2 0.3 0.47
Rey ﬁgure drawing 8.0  5.1 0.5 0.6
Rey ﬁgure immediate recall 6.1  4.3 0.2 0.62
Rey ﬁgure delayed recall 5.8  4.1 0.2 0.59
MQ (memory quotient) 81.2  11.8 3.8 0.06
Korean version of Memory Assessment Scales (K-MAS)
Short term memory 78.5  21.0 0.0 1.00
Verbal memory 79.2  16.9 6.2 0.17
Visual memory 81.6  18.7 1.8 0.72
Total memory 77.3  17.1 5.3 0.16
Frontal lobe function and attention
MMSE 25.3  3.7 0.1 0.85
Trail Making Test
Time on part A 90.8  80.6 5.4 0.81
Time on part B 140.0  119.7 4.5 0.89
Digit Span forward 6.1  2.1 0.3 0.34
Digit Span backward 3.6  1.9 0.1 0.78
Word Fluency Test
Category 18.2  7.2 2.5 0.03
Letter 17.4  10.1 5.2 0.043
Digit Symbol 7.2  3.0 0.2 0.68
Frontal Assessment Battery 14.7  3.2 0.2 0.72
Pegboard test
Right hand 240.7  219.2 0.1 0.99
Left hand 248.8  225.7 25.7 0.36
Wisconsin Card Sorting Test
Number of correct responses 37.3  15.5 7.0 0.10
Perseverative errors 40.5  16.5 4.7 0.36
Nonperseverative errors 45.3  11.2 0.7 0.88
a Changes from baseline to the end of the long-term phase (NP testing score at
least 12 months after baseline evaluation).
y p values in boldface are statistically signiﬁcant (p < 0.05, paired t-test).changes to each of the twenty-seven domains of our NP testing.
Statistical signiﬁcance of all tests was evaluated at a signiﬁcance
level of 0.05. Statistical analyses were performed using SPSS 12.0
(SPSS, Inc., Chicago, IL).
3. Results
3.1. Demographic characteristics of patients
The age of patients at surgery ranged from 14 to 49 years. Four
patients were male. The duration of epilepsy ranged from 8 to 39
years. All patients had experienced more than 2 years of post-
operative follow-up, ranging from 22 to 60 months (mean
34.6  16.6 months). Post-operative NP assessments were performed
after more than 1 year (mean 15.9  5.0 months) after the ATN DBS
operation.
All nine patients had complex partial seizures evolving to
secondary generalized seizures. Their ictal onsets were not
lateralized or were multifocal (Table 1). After long term follow-
up, 7 (77.8%) of our patients experienced a signiﬁcant reduction in
their seizure frequency (>50% seizure reduction). The overall mean
seizure-reduction rate of nine patients after ATN DBS was 57.9%
(35.6–90.4%, Table 3).
3.2. Neuropsychological data
Results were favorable for the word ﬂuency tasks (letter and
category, p < 0.05), and a signiﬁcant improvement was observed
on the RKMT of delayed verbal memory (p = 0.017) after DBS
procedures. There were no signiﬁcant changes in general abilities
(IQ, MMSE), information processing (digit forward and backward,
Trail A, and Digit-Symbol Substitution), or executive function (Trail
B, FAB, and WCST). Detailed neuropsychological testing results are
described in Tables 4 and 5.
Intriguingly, there was no statistically signiﬁcant correlation
between clinical effect after ATN DBS (seizure reduction rate) and
the NP measurements; delayed verbal recall (r = 0.505, p = 0.17),
Word Fluency Test (letter, r = 0.276, p = 0.47; category,
r = 0.011, p = 0.98), as well as the other NP domains (verbal,
performance and total IQ; short term, visual and total memory;
various frontal lobe function tests including TMT-A and B, and
WCST).
4. Discussion
ATN is a collection of deep nuclei thought to affect not only the
modulation of alertness but also learning and memory. Prior
clinical studies have shown that ATN dysfunction may be
Table 5
Raw data of NP testing at baseline before surgery and after chronic ATN DBS.
Patient p-Value*
1 2 3 4 5 6 7 8 9
Verbal IQ
Baseline 106 82 78 71 112 79 95 72 101 0.40
Post-op 100 78 81 73 123 78 98 74 98
Performance IQ
Baseline 112 71 70 75 106 89 96 74 86 0.85
Post-op 112 75 73 71 103 90 96 83 89
Full scale IQ
Baseline 109 75 71 73 110 82 95 72 94 0.42
Post-op 105 76 82 71 116 88 97 75 93
Delayed verbal recall
Baseline 8 9 9 6 7 1 11 4 8 0.017
Post-op 9 8 10 9 10 6 11 8 11
Word Fluency Test
Category
Baseline 31 19 24 15 21 13 19 16 20 0.03
Post-op 37 18 24 17 28 15 15 15 24
Letter
Baseline 24 13 24 14 24 12 34 5 18 0.043
Post-op 43 19 20 13 27 16 42 14 19
* Comparison of data measured at baseline vs. post-ATN DBS operation state; p-values in boldface are statistically signiﬁcant (p < 0.05, paired t-test).
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episodic memory).13
However, cognitive decline after chronic ATN DBS has not been
noticed in some case studies.3,4 Only a brief and limited description
on the general intelligence quotient (IQ) test results after ATN DBS
was reported.14 In SANTE trial, a subjective deterioration of
memory function was reported in 13% of patients during the initial
period (for 3 months after surgery). But it was neither serious in
severity nor maintained chronically (all resolved over 12–476
days).5 To our knowledge, we now provide the ﬁrst long-term NP
data concerning the full cognitive function of ATN DBS patients
with intractable epilepsy.
Our patients did not show any meaningful decline in various NP
domains after chronic ATN stimulation. Moreover, word ﬂuency
and delayed verbal memory were signiﬁcantly improved after the
procedure. We can hypothesize several underlying mechanisms of
the beneﬁcial effects observed after ATN DBS on cognition besides
its antiepileptic effects.
First, we assumed that electrical stimulation of ATN also
directly activated the limbic memory circuit and the associated
thalamo-cortical pathway, resulting in signiﬁcant improvement
in verbal memory or verbal ﬂuency after chronic stimulation.
This hypothesis is supported by some recent studies. Bilateral
ATN stimulation of the rat brain reversibly increased glucose
uptake in connected thalamic nuclei and both hippocampi,
which might be attributed to excitation of efferent thalamo-
hippocampal projections from the ATN.15 A case study with
long-term hypothalamic/fornix stimulation for controlling
morbid obesity provided interesting data showing that hippo-
campus-dependent memory improvement originated from the
activation of the hippocampal memory circuit through stimula-
tion of the fornix.16 In that case, the hypothalamic/fornix
stimulation also induced some improvement of verbal ﬂuency
(phonemic and semantic). This may reﬂect a contributing role of
the medial temporal regions not only to memory but also to
language, due to their close interaction with neighboring
neocortical structures specialized in language processing,17
such as perirhinal cortex18 in our ATN DBS patients.
Second, we can suppose that the improved cognitive function
originated from decreased AED dosage or reduced seizure
frequency. Four among our patients had been under topiramate(TPM), which is most likely to induce deﬁcits in working memory,
and verbal ﬂuency.19,20 Minimal reduced dosage of TPM in one
patient (400–300 mg per day, patient 2) was accompanied by
supplementing the levetiracetam (LEV) for controlling her
refractory seizures. LEV administration may have a favorable
impact or even improvement in some of NP measures, such as
attention, verbal ﬂuency and memory functions.21–23 But the
minimal AED compositional change and dosage adjustment did not
seem to have a great inﬂuence on the overall neuro-cognitive data
we observed in this study (Tables 2 and 5), especially on patient 2
(whose delayed verbal recall and categorial word ﬂuency did not
improve after ATN DBS).
Third, we could ﬁnd that a good clinical outcome was not a
univariate predictor of any of the NP domains. There was no
difference in the NPT data obtained between our seven patients
(patients 1, 3, 4, 6, 7, 8 and 9), who achieved more than a 50%
seizure reduction, and the other patients (patients 2 and 5) with
50% reduction (data not shown). Finally, we cannot exclude a
practice effect from repeated NP assessment may not be excluded.
However, practice is likely to have had a minimal or negligible
effect on follow-up NP testing performed at least 1 year post-
surgery.
In conclusion, the effects of bilateral ATN DBS on cognition
shown here represent an interesting collateral effect in the context
of antiepileptic treatment for intractable epilepsy. Clinical
considerations regarding ATN DBS for treating refractory epilepsy
are in the early stages, and additional convincing data of the
chronic inﬂuence of DBS on the cognition or behavior will be
forthcoming.
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